Oflofine OZ Tablet is a combination antibiotic formulation containing Ofloxacin 200 mg and Ornidazole 500 mg, designed for the treatment of mixed bacterial and protozoal infections. Ofloxacin, a fluoroquinolone antibiotic, exhibits broad-spectrum bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication and transcription. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by disrupting DNA synthesis and inducing strand breakage. This synergistic combination is particularly useful in managing infections where both aerobic and anaerobic pathogens are implicated, such as gastrointestinal infections, intra-abdominal abscesses, pelvic inflammatory disease, and certain respiratory tract infections. Oflofine OZ is indicated for adults and adolescents with confirmed or suspected mixed infections, ensuring comprehensive antimicrobial coverage. The tablet should be administered as prescribed by a healthcare professional, with dosage adjustments considered based on renal function and severity of infection. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and potential side effects include gastrointestinal disturbances, dizziness, and hypersensitivity reactions. Proper adherence to prescribed therapy is essential to prevent resistance development and achieve optimal clinical outcomes.